Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of alzheimer's disease-related pathology

Journal of Neuroscience

Volumn 32, Issue 30, 2012, Pages 10201-10210

  Bachstetter, Adam D ^a   Norris, Christopher M ^a,b   Sompol, Pradoldej ^a   Wilcock, Donna M ^a,b   Goulding, Danielle ^a   Neltner, Janna H ^a,b   Daret, St ^a,b,c   Watterson, D Martin ^d   van Eldik, Linda J ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; MESSENGER RNA; MW 151; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN S100B; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN; UNCLASSIFIED DRUG; VIMENTIN;

AGE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; EARLY INTERVENTION; ELECTROPHYSIOLOGY; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LOW DRUG DOSE; MALE; MICROGLIA; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEPLETION; WESTERN BLOTTING;

AGING; ALZHEIMER DISEASE; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HIPPOCAMPUS; MICE; MICE, TRANSGENIC; MICROGLIA; NEURONS; PYRIDAZINES; PYRIMIDINES; SYNAPSES;

EID: 84864237721     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1496-12.2012     Document Type: Article

References (60)

1. P264L/P264L double knock-in mouse model of Alzheimer's disease. Am J Pathol 168:1608-1618.
2. Bliss TVP, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31-39.
3. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN, ADAP Research Group (2011) Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 7:402-411.
4. Bruce-Keller AJ, Gupta S, Knight AG, Beckett TL, McMulle JM, Davis PR, Murphy MP, Van Eldik LJ, St Clair D, Keller JN (2011) Cognitive impairment in humanized APPXPS1 mice is linked to Aβ1-42 and NOX activation. Neurobiol Dis 44:317-326.
5. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB (2001) In-vivo measurement of activated microglia in dementia. Lancet 358:461-467.
6. Cameron B, Landreth GE (2010) Inflammation, microglia and Alzheimer's disease. Neurobiol Dis 37:503-509.
7. 18F-FDG. J Nucl Med 53:37-46.
8. Chang EH, Savage MJ, Flood DG, Thomas JM, Levy RB, Mahadomrongkul V, Shirao T, Aoki C, Huerta PT (2006) AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. Proc Natl Acad Sci U S A 103:3410-3415.
9. Chrzaszcz M, Venkatesan C, Dragisic T, Watterson DM, Wainwright MS (2010) Minozac treatment prevents increased seizure susceptibility in a mouse "two-hit" model of closed skull traumatic brain injury and electroconvulsive shock-induced seizures. J Neurotrauma 27:1283-1295.
10. Cowley TR, O'Sullivan J, Blau C, Deighan BF, Jones R, Kerskens C, Richardson JC, Virley D, Upton N, Lynch MA (2012) Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP. Neurobiol Aging 33:162-175.
11. Craft JM, Watterson DM, Frautschy SA, Van Eldik LJ (2004a) Aminopyridazines inhibit β-amyloid induced glial activation and neuronal damage in vivo. Neurobiol Aging 25:1283-1292.
12. Craft JM, Van Eldik LJ, Zasadzki M, Hu W, Watterson DM (2004b) Aminopyridazines attenuate hippocampus dependent behavioral deficits induced by human Aβ in a murine model of neuroinflammation. J Mol Neurosci 24:115-122.
13. Eroglu C, Barres BA (2010) Regulation of synaptic connectivity by glia. Nature 468:223-231.
14. Flood DG, Reaume AG, Dorfman KS, Lin YG, Lang DM, Trusko SP, Savage MJ, Annaert WG, De Strooper B, Siman R, Scott RW (2002) FAD mutant PS-1 gene-targeted mice: increased Aβ42 and Aβ deposition without APP overproduction. Neurobiol Aging 23:335-348.
15. Griffin R, Nally R, Nolan Y, McCartney Y, Linden J, Lynch MA (2006) The age-related attenuation in long-term potentiation is associated with microglial activation. J Neurochem 99:1263-1272.
16. Griffin WST, Barger SW (2010) Neuroinflammatory cytokines-the common thread in Alzheimer's pathogenesis. US Neurol 6:19-27.
17. Guerreiro RJ, Gustafson DR, Hardy J (2012) The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging 33:437-456.
18. He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, Staufenbiel M, Li R, Shen Y (2007) Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 178:829-841.
19. Hein AM, Stasko MR, Matousek SB, Scott-McKean JJ, Maier SF, Olschowka JA, Costa ACS, O'Banion MK (2010) Sustained hippocampal IL-1βoverexpression impairs contextual and spatial memory in transgenic mice. Brain Behav Immun 24:243-253.
20. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148:1204-1222.
21. Hu W, Ralay Ranaivo H, Roy SM, Behanna HA, Wing LK, Munoz L, Guo L, Van Eldik LJ, Watterson DM (2007) Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett 17:414-418.
22. in't Veld BA, Ruitenberg A, Hofman A, Launer LJ, Van Duijn CM, Stijnen T, Breteler MMB, Stricker BHC (2001) Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345:1515-1521.
23. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN (2002) Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22:2246-2254.
24. Karpus WJ, Reynolds N, Behanna HA, Van Eldik LJ, Watterson DM (2008) Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight pro-inflammatory cytokine suppressing drug. J Neuroimmunol 203:73-78.
25. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM (2011) Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol 187:6539-6549.
26. Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, Lesne S, Falinska A, Younkin LH, Younkin SG, Rowan M, Cleary J, Wallis RA, Sun GY, Cole G, Frautschy S, Anwyl R, Ashe KH (2008) Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 131:651-664.
27. Leoutsakos J-MS, Muthen BO, Breitner JCS, Lyketsos CG, For the ADAP Research Team (2012) Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's disease anti-inflammatory prevention trial. Int J Geriatr Psychiatry 27:364-374.
28. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20:5709-5714.
29. Lloyd E, Somera-Molina KC, Van Eldik LJ, Watterson DM, Wainwright MS (2008) Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurology outcome in a mouse model of traumatic brain injury. J Neuroinflammation 5:28.
30. Lynch MA (2010) Age-related neuroinflammatory changes negatively impact on neuronal function. Front Aging Neurosci 1:6.
31. Malenka RC, Nicoll RA (1999) Long-term potentiation-a decade of progress? Science 285:1870-1874.
32. Mathis DM, Furman JL, Norris CM (2011) Preparation of acute hippocampal slices from rats and transgenic mice for the study of synaptic alterations during aging and amyloid pathology. J Vis Exp p2:2330.
33. McGeer PL, Schulzer M, McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47:425-432.
34. Morihara T, Teter B, Yang F, Lim GP, Boudinot S, Boudinot FD, Frautschy SA, Cole GM (2005) Ibuprofen suppresses interleukin-1β induction of pro-amyloidogenic α2-antichymotrypsin to ameliorate β-amyloid (A β) pathology in Alzheimer's models. Neuropsychopharmacology 30: 1111-1120.
35. Mrak RE, Griffin WST (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26:349-354.
36. Murphy MP, Beckett TL, Ding Q, Patel E, Markesbery WR, St Clair DK, LeVine H 3rd, Keller JN (2007) Aβ solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis 27:301-311.
37. Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 68:1-14.
38. Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA, Abner EL, Smith CD, Van Eldik LJ, Kryscio RJ, Scheff SW (2011) Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol 121:571-587.
39. Norris CM, Scheff SW (2009) Recovery of afferent function and synaptic strength in hippocampal CA1 following traumatic brain injury. J Neurotrauma 26:2269-2278.
40. Ralay Ranaivo H, Craft JM, Hu W, Guo L, Wing LK, Van Eldik LJ, Watterson DM (2006) Glia as a therapeutic target: selective suppression of human amyloid-β-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 26:662-670.
41. Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27:119-145.
42. Reaume AG, Howland DS, Trusko SP, Savage MJ, Lang DM, Greenberg BD, Siman R, Scott RW (1996) Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Aβ sequence. J Biol Chem 271:23380-23388.
43. Rowan MJ, Klyubin I, Wang Q, Hu NW, Anwyl R (2007) Synaptic memory mechanisms: Alzheimer's disease amyloid β-peptide-induced dysfunction. Biochem Soc Trans 35:1219-1223.
44. Sama MA, Mathis DM, Furman JL, Abdul HM, Artiushin IA, Kraner SD, Norris CM (2008) Interleukin-1β-dependent signaling between glia and neurons depends critically on astrocytic calcineurin/NFAT activity. J Biol Chem 283:21953-21964.
45. Shaftel SS, Griffin WST, O'Banion MK (2008) The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 5:7.
46. Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, Scott RW, Flood DG (2000) Presenilin-1 P264L knock-in mutation: differential effects on Aβ production, amyloid deposition, and neuronal vulnerability. J Neurosci 20:8717-8726.
47. Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, Van Broeckhoven C (2010) The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet 26:84-93.
48. Somera-Molina KC, Robin B, Somera CA, Anderson C, Koh S, Behanna HA, Van Eldik LJ, Watterson DM, Wainwright MS (2007) Glial activation links early-life seizures and long-term neurologic dysfunction: evidence using a small molecule inhibitor of pro-inflammatory cytokine upregulation. Epilepsia 48:1785-1800.
49. Somera-Molina KC, Nair S, Van Eldik LJ, Watterson DM, Wainwright MS (2009) Enhanced microglial activation and proinflammatory cytokine upregulation are linked to increased susceptibility to seizures and neurologic injury in a 'two-hit' seizure model. Brain Res 1282:162-172.
50. Tremblay MÈ, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A (2011) The role of microglia in the healthy brain. J Neurosci 31:16064-16069.
51. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O (2004) Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 55:801-814.
52. Van Eldik LJ, Thompson WL, Ralay Ranaivo H, Behanna HA, Watterson DM (2007) Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int Rev Neurobiol 82:277-296.
53. Wing LK, Behanna HA, Van Eldik LJ, Watterson DM, Ralay Ranaivo H (2006) De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders. Curr Alzheimer Res 3:205-214.
54. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2:a006346.
55. Xing B, Bachstetter AD, Van Eldik LJ (2011) Microglia p38α MAPK is critical for LPS-induced neuron degeneration through a mechanism involving TNFα. Mol Neurodegener 6:84.
56. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T (2007) Interferon-β and tumor necrosis factor-γ regulate amyloid-α plaque deposition and β-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 170:680-692.
57. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G (2003) Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23:7504-7509.
58. Yirmiya R, Goshen I (2011) Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 25:181-213.
59. Zandi PP, Breitner JCS (2001) Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 22: 811-817.
60. Zilka N, Kazmerova Z, Jadhav S, Neradil P, Madari A, Obetkova D, Bugos O, Novak M (2012) Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflammation 9:47.